Searchable abstracts of presentations at key conferences in endocrinology

ea0035p606 | Endocrine tumours and neoplasia | ECE2014

Breast metastasis from medullary thyroid carcinoma in a man

Mandanas Stylianos , Margaritidou Efterpi , Georgopoulos Konstantinos , Boudina Maria , Chrisoulidou Alexandra , Pazaitou-Panayiotou Kalliopi

Introduction: Medullary thyroid carcinoma (MTC) originated from parafollicular C cells of the thyroid gland is a rare histological type of malignancy. Common sites of metastases are liver, lungs and bones, while metastases in other sites are extremely rare. Breast metastases from MTC are reported in 20 cases, and only in women.Case report: A 67-year-old man was presented after thyroidectomy for further evaluation and treatment. Histology was positive for...

ea0032p1091 | Thyroid cancer | ECE2013

Treating refractory thyroid cancer in the era of multitarget tyrosine kinase inhibitors

Mathiopoulou Lemonia , Boudina Maria , Chrisoulidou Alexandra , Mandanas Stylianos , Margaritidou Efterpi , Georgopoulos Konstantinos , Pazaitou-Panayiotou Kalliopi

Introduction: Tyrosine kinase inhibitors (sorafenib and sunitinib) have been used in treating refractory cases of thyroid cancer. The aim of our present study was to assess the efficacy of these agents in patients with refractory and progressive thyroid cancer, regarding patientsÂ’ quality of life, adverse events and response ratesPatients and methods: We retrospectively analyzed data of adult patients with differentiated and medullary thyroid cancer...

ea0032p75 | Bone and Osteoporosis | ECE2013

Calcium homeostasis in women with non-metastatic breast cancer with osteoporosis after a single-dose of denosumab: a pilot study

Mandanas Stylianos , Toulis Konstantinos , Mathiopoulou Lemonia , Margaritidou Efterpi , Georgopoulos Konstantinos , Boudina Maria , Chrisoulidou Alexandra , Pazaitou-Panayiotou Kalliopi

Introduction: Women with non-metastatic breast cancer form a distinct subpopulation in which calcium homeostasis in response to treatment with denosumab has not been extensively investigated.Methods: Female patients with osteoporosis, who were eligible for treatment with denosumab, were prospectively enrolled (2011–2012) and divided into two groups; Group A consisting of patients with either no history or benign diseases non affecting bone metabolis...